skinc cancer
Keytruda continues success with new Phase 3 data in adjuvant melanoma
April 16, 2018Research and Development, Sales and Marketing Cancer, MSD, keytruda, melanoma, pharma, skinc cancer
MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
